Ignite Creation Date:
2024-05-06 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06179693
Status:
COMPLETED
Last Update Posted:
2023-12-22
First Post:
2023-12-01
Brief Title:
AIMN Multicenter Study Staging of Lymphomas Using PETCT
Sponsor:
IRCCS San Raffaele
Organization:
IRCCS San Raffaele
Study Overview
Official Title:
AIMN Multicenter Study Staging of Lymphomas Using PETCT
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In recent years the introduction of PETCT tomographs which have now almost completely replaced tomographs equipped with PET alone has allowed a significant increase in diagnostic accuracy in the majority of tumors However in order to reduce the radiation doses administering CT images are acquired for patients at a low dose generally 60mA 120kV without the use of contrast agents This prudential attitude however makes it essential to carry out diagnostic CT investigations which at the end of the diagnostic process It leads to an increase in the dose administered for the patient rather than to savings
This study aims to evaluate the possible advantages in diagnostic economic and quality of life terms of PETCT performed with diagnostic CT with intravenous contrast medium with the aim of benefiting the neoplastic patient in the diagnostic process by optimizing from a temporal and dosimetric point of view the diagnostic procedures to which it is subjected
It is expected that the integrated PETCT procedure can facilitate the process of staging the neoplasm and that this procedure can have a positive impact on the patients quality of life while also reducing the costs incurred in terms of time and money
This study aims to evaluate the possible advantages in diagnostic economic and quality of life terms of PETCT performed with diagnostic CT with intravenous contrast medium with the aim of benefiting the neoplastic patient in the diagnostic process by optimizing from a temporal and dosimetric point of view the diagnostic procedures to which it is subjected
It is expected that the integrated PETCT procedure can facilitate the process of staging the neoplasm and that this procedure can have a positive impact on the patients quality of life while also reducing the costs incurred in terms of time and money
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None